Monthly Archive: April 2015

Apr 30

If all 75- to 94-year-olds living in the US in 2014 received generic statins for 10 years for primary prevention of MIs and death from CHD

If all 75- to 94-year-olds living in the US in 2014 received generic statins for 10 years for primary prevention of MIs and death from CHD, this would be cost-effective, but only when geriatric-specific side effects—that is, functional limitations (muscle pain and weakness) and mild cognitive impairment—were excluded, researchers conclude. (April 21, 2015 issue of …

Continue reading »

Apr 30

Digoxin, a cardiac glycoside, has inotropic effects in addition to effects on cardiac output

Digoxin, a cardiac glycoside, has inotropic effects in addition to effects on cardiac output. Digoxin is used to treat heart failure and atrial fibrillation and has other off-label uses. It has been shown to reduce hospitalization rates without affecting mortality rates in patients with heart failure. Digoxin is effective for rate control in patients with …

Continue reading »

Apr 29

A very early and more intensive rehabilitation program seems to be associated with a reduced likelihood of achieving a favorable outcome at 3 months vs. usual care

A very early and more intensive rehabilitation program seems to be associated with a reduced likelihood of achieving a favorable outcome at 3 months vs. usual care, reported the first large-scale randomized trial of rehabilitation therapy in patients with acute stroke published online in The Lancet.

Apr 29

Patients with atrial fibrillation, especially women

Patients with atrial fibrillation, especially women, may be at significant risk for a non-ST-segment-elevation MI (NSTEMI), suggests a new analysis from the Atherosclerosis Risk in Communities (ARIC) study published online in Circulation.

Apr 28

Vascular calcifications in the hand radiographs of rheumatoid arthritis (RA)

Vascular calcifications in the hand radiographs of rheumatoid arthritis (RA) patients are associated with more than 40% increased risk of all-cause mortality, and these radiographic vascular calcifications may be markers of cardiovascular disease (CVD) risk, suggests a multicenter Veterans Affairs study published online in Rheumatology.

Apr 28

Although the severity of hypertension or magnitude of cardiovascular risk

Although the severity of hypertension or magnitude of cardiovascular risk do not affect the relative risk reduction of major cardiovascular events with antihypertensive therapy, the absolute benefit of antihypertensive therapy is greater in patients with more severe hypertension or greater overall cardiovascular risk. (Contributed by Dr Ravi Kasliwal)

Apr 27

The new oral anticoagulant edoxaban has received approval recommendation from the European Medicines Agency (EMA)

The new oral anticoagulant edoxaban has received approval recommendation from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) for use in the prevention of stroke and systemic embolism in patients with nonvalvular AF, as well as for prevention and treatment of recurrent venous thromboembolism.

Apr 27

A novel breast arterial calcification (BAC)

A novel breast arterial calcification (BAC) score that uses findings from standard digital mammography predicts underlying coronary calcification and cardiovascular disease risk, reported a new study presented at the American Roentgen Ray Society 2015 Annual Meeting.

Apr 26

suggest the results from a meta-analysis published April 22 in the BMJ.

Even after 60 years of age, quitting smoking for 5 years translates into a significant reduction in cardiovascular mortality when compared with individuals who continue to smoke, suggest the results from a meta-analysis published April 22 in the BMJ.

Apr 26

An article published in the April 21 issue of the Annals of Internal Medicine suggests that if all 75- to 94-year-olds living in the US in 2014

An article published in the April 21 issue of the Annals of Internal Medicine suggests that if all 75- to 94-year-olds living in the US in 2014 received generic statins for 10 years for primary prevention of MIs and death from CHD, this would be cost-effective, but only when geriatric-specific side effects including functional limitations …

Continue reading »

Older posts «